Exelixis (EXEL) Operating Expenses (2010 - 2026)
Exelixis (EXEL) posted quarterly Operating Expenses of $359.5 million for Q2 2026, down 2.47% year-over-year from $368.6 million in Q2 2025, and down 1.09% quarter-over-quarter from $363.4 million in Q1 2026.
Analysis
Exelixis (EXEL) Operating Expenses (2010 - 2026) Analysis & Trends
Exelixis' Operating Expenses history runs 17 years deep, the most recent figure standing at $359.5 million for Q2 2026.
- In Q2 2026, Operating Expenses fell 2.47% year-over-year to $359.5 million; the TTM figure through Apr 2026 stood at $1.4 billion (down 6.38% YoY), while the FY2026 annual figure was $1.4 billion, down 7.43% from the prior year.
- Operating Expenses for Q2 2026 stood at $359.5 million, down from $363.4 million in the prior quarter.
- The five-year high for Operating Expenses was $489.5 million in Q3 2023, with the low at $272.7 million in Q2 2022.
- The 5-year median for Operating Expenses is $368.6 million (2025), against an average of $378.8 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 48.73% in 2023, then retreated 17.58% in 2024.
- Exelixis' Operating Expenses stood at $472.0 million in 2022, then fell by 15.71% to $397.9 million in 2023, then rose by 1.41% to $403.5 million in 2024, then decreased by 10.47% to $361.2 million in 2025, then declined by 0.48% to $359.5 million in 2026.
- Business Quant data shows EXEL's Operating Expenses at $359.5 million in Q2 2026, $363.4 million in Q1 2026, and $361.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 380.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 380.28 Mn |
| Apr 3, 2026 | 359.47 Mn |
| Jan 2, 2026 | 363.45 Mn |
| Oct 3, 2025 | 361.22 Mn |
| Jul 4, 2025 | 354.69 Mn |
| Apr 4, 2025 | 368.59 Mn |
| Jan 3, 2025 | 403.55 Mn |
| Sep 27, 2024 | 403.47 Mn |
| Jun 28, 2024 | 361.30 Mn |
| Mar 29, 2024 | 395.76 Mn |
| Dec 29, 2023 | 397.86 Mn |
| Sep 29, 2023 | 489.50 Mn |
| Jun 30, 2023 | 392.00 Mn |
| Mar 31, 2023 | 379.96 Mn |
| Dec 30, 2022 | 472.00 Mn |
| Sep 30, 2022 | 329.13 Mn |
| Jul 1, 2022 | 335.72 Mn |
| Apr 1, 2022 | 272.74 Mn |
| Dec 31, 2021 | 334.50 Mn |
| Oct 1, 2021 | 276.80 Mn |